摘要
目的:探讨CD19在AML1-ETO阳性急性髓系白血病(Acute myelogenous leukemia with AML1-ETO positive,AML with AML1-ETO positive)患者中的表达及对预后的影响。方法:收集我中心2010年1月至2015年12月共66例初治AML1-ETO阳性AML患者资料,回顾性分析CD19表达与一般临床特征的关系及对生存期的影响。结果:AML1-ETO阳性AML患者初诊时CD19的表达率为50.0%。CD19阳性与阴性患者在年龄、性别、初诊时血红蛋白、血小板、骨髓原始细胞比例、染色体核型、基因突变无统计学差异(P>0.05)。CD19阳性患者初诊时白细胞计数低于阴性患者,有统计学差异(P=0.027)。CD19阳性患者总体生存率明显优于CD19阴性患者(P=0.030),CD19阳性患者无复发生存率较阴性患者高,但差异无统计学意义(P=0.105)。多因素分析结果提示CD19阳性是AML1-ETO阳性AML患者OS的独立预后良好因素。结论:CD19阳性可能是AML1-ETO阳性AML患者预后良好的标志。
Objective： To investigate the expression and prognostic significance of CD19 in patients with Acute myelogenous leukemia with AML1-ETO positive. Methods： Clinical data of 66 patients AML with AML1-ETO positive who were newly diagnosed from Jan 2010 to Dec 2015 were collected. To retrospectively analyze the relationship between clinical characteristics and expression of CD19,so dose the prognosis. Results： The positive rate of CD19 expressing in AML with AML1-ETO positive was 50. 0%. There were no statistically significant differences in terms of age,gender,hemoglobin,platelet,percentage of bone marrow blasts,accompanied with chromosome,gene mutations between patients with and without CD19 expression（ P〉0. 05）. The white blood cell count（ WBC） of the CD19 negative group was higher than CD19 positive group,while showed significant difference（ P = 0. 027）. Although the relapse-free survival（ RFS） of patients with CD19 expression was higher than those without,no significant difference was calculated（ P = 0. 105）.Patients with CD19 expression had superior overall survival（ OS） compared to those without CD19 expression（ P = 0. 030）. Multivariable analysis for OS identified CD19 positivity as an independent predictor associated with better prognosis. Conclusion： The expression of CD19 in AML with AML1-ETO positive may be an indicator associated with better prognosis.
作者
边程
何平
王畅
刘晓亮
刘杉珊
林海
谭业辉
高素君
BIAN Cheng HE Ping WANG Chang LIU Xiao-Liang LIU Shah-Shah LIN Hai TAN Ye-Hui GAO Su- Jun(Hematology Department Cancer Cenler, the First Bethune Hospital of Jilin University, Changchun 130021, China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2016年第12期1809-1814,共6页
Chinese Journal of Immunology
基金
吉林省科技发展计划(20070729-22)资助
